Promising Imaging Data and Future Trials Support Buy Rating for Bicycle Therapeutics

Analyst Ami Fadia of Needham maintained a Buy rating on Bicycle Therapeutics (BCYC – Research Report), reducing the price target to $29.00.

Ami Fadia’s rating is based on the promising human imaging data for Bicycle Therapeutics’ MT1-MMP BRC, which was presented at the AACR. The data demonstrated that the BRC tracer effectively targets primary tumors and metastatic lesions, showing potential across various tumor types such as lung, HNSCC, and bladder. This broad applicability across different cancers enhances the therapeutic potential of Bicycle Therapeutics’ technology.
Ami Fadia also notes the variability in tracer uptake depending on the imaging technique used, though the significance of these differences remains unclear. The MT1-MMP-PET imaging technique, which targets the membrane type 1-matrix metalloproteinase, may offer a more precise depiction of the tracer’s effectiveness. The company’s plan to initiate clinical radiopharmaceutical trials in 2026 and the anticipation of initial human imaging data for BRC EphA2 in the second half of 2025 further support the Buy rating, as these steps indicate a clear path forward in the development of their pipeline.

Fadia covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Jazz Pharmaceuticals, and Bicycle Therapeutics. According to TipRanks, Fadia has an average return of -2.0% and a 38.94% success rate on recommended stocks.